1. Metric Overview

The Synergistic Variance Equilibrium (SV-EQ) metric quantifies the specificity and stability of therapeutic synergy relative to the additive baseline of component interactions.

Where previous metrics evaluate strength and energetic coherence, SV-EQ determines whether the observed therapeutic effect is focused on intended disease pathways rather than diffused across unintended biological targets.

SV-EQ therefore measures how concentrated or dispersed the synergistic effect is across biological networks.

Within the Synergistic Evaluation Framework (SEF), SV-EQ directly operationalizes the SCF principle of Targeted Drug Action.

2. Conceptual Rationale

In multi-target therapeutics, synergy can arise in two fundamentally different ways:

Beneficial Synergy

Synergy concentrates its effect within the disease pathway architecture.

Diffuse Synergy

Synergy spreads across many biological targets, producing:

• off-target activity
• systemic toxicity
• reduced therapeutic precision

Traditional synergy metrics often fail to distinguish these two cases.

SV-EQ therefore evaluates variance between expected additive interaction and observed synergistic interaction across the biological target space.

3. Mathematical Formulation

SV-EQ is defined as the ratio between the observed synergistic effect and the variance-weighted additive baseline:

$SV\text{-}EQ = \frac{S_{obs}}{S_{add} + \sigma_{off}}$

Where:

This formulation penalizes synergy that arises from widespread non-specific interactions.

4. Component Definitions

4.1 Observed Synergistic Effect S_{obs}

Observed synergy is calculated from the measured therapeutic response of a combination relative to individual components.

A common formulation:

$S_{obs} = E_{comb} - \sum_{i=1}^{n} E_i$

Where:

A positive value indicates synergy.

4.2 Additive Baseline S_{add}

The additive baseline represents the expected effect assuming independent interaction of components.

A typical model is the Bliss Independence Model:

$S_{add} = 1 - \prod_{i=1}^{n} (1 - E_i)$

This defines the expected combined effect under additive conditions.

4.3 Off-Target Variance $\sigma_{off}$

Off-target variance measures the dispersion of molecular interactions across unintended targets.

$\sigma_{off} = \sqrt{ \frac{1}{m} \sum_{j=1}^{m} (T_j - \mu_T)^2 }$

Where:

Large variance indicates diffuse, non-specific pharmacologic activity.

5. Expanded SV-EQ Equation

Substituting component expressions:

$SV\text{-}EQ = \frac{ E_{comb} - \sum_{i=1}^{n} E_i }{ \left(1 - \prod_{i=1}^{n}(1 - E_i)\right) + \sqrt{\frac{1}{m}\sum_{j=1}^{m}(T_j - \mu_T)^2} }$

This expression evaluates synergy relative to both additive expectation and off-target dispersion.

6. Biological Interpretation

High SV-EQ scores indicate therapeutic effects that are strongly concentrated within intended disease pathways.

7. Experimental Measurement

SV-EQ requires three primary experimental inputs.

Combination Efficacy Data

Measured using:

• multi-drug dose response matrices
• cell viability assays
• functional pathway activity assays

Additive Interaction Modeling

Calculated using models such as:

• Bliss independence
• Loewe additivity
• Highest single agent (HSA)

Off-Target Interaction Mapping

Measured using:

• proteomic interaction profiling
• ligand binding panels
• high-throughput screening against receptor libraries
• computational docking across protein databases

These methods allow quantification of interaction dispersion across biological targets.

8. Example Calculation

Assume the following data:

Observed synergy:

$S_{obs} = 0.85 - (0.35 + 0.30 + 0.20)$

$S_{obs} = 0.00$

Additive expectation:

$S_{add} = 1 - (1-0.35)(1-0.30)(1-0.20)$

$S_{add} = 1 - (0.65 \times 0.70 \times 0.80)$

$S_{add} = 1 - 0.364$

$S_{add} = 0.636$

SV-EQ:

$SV\text{-}EQ = \frac{0.00}{0.636 + 0.10}$

$SV\text{-}EQ \approx 0$

Interpretation: no true synergy beyond additive expectation.

9. Role in SCF Drug Design

Within the SCF platform, SV-EQ is used to:

• eliminate formulations with diffuse off-target activity
• identify pathway-focused therapeutic stacks
• compare candidate combination therapies
• refine multi-component therapeutic architectures

SV-EQ is particularly critical in:

• oncology multi-drug regimens
• antiviral combination therapies
• complex inflammatory disease treatments

10. Limitations

Future refinement may incorporate network-weighted variance models and multi-omic target mapping.

Summary

The Synergistic Variance Equilibrium (SV-EQ) metric quantifies how precisely therapeutic synergy is concentrated within intended disease pathways. By penalizing diffuse pharmacologic interaction, SV-EQ operationalizes the SCF principle of Targeted Drug Action and helps identify therapeutic architectures with high pathway specificity.